Organon (OGN) Other Non Operating Income (2020 - 2026)
Organon (OGN) posted quarterly Other Non Operating Income of -$29.0 million for Q2 2026, down 182.86% year-over-year from $35.0 million in Q2 2025, and down 130.21% on a QoQ basis from $96.0 million in Q1 2026.
Organon (OGN) Other Non Operating Income (2020 - 2026) Analysis & Trends
Organon has reported Other Non Operating Income for 7 years, with the latest figure at -$29.0 million in Q2 2026.
- Other Non Operating Income for Q2 2026 came in at -$29.0 million, down 182.86% year-over-year; the trailing twelve-month figure through Jun 2026 was $163.0 million (up 8050.0% YoY), and the FY2025 annual result was $119.0 million, up 557.69% from the prior year.
- Other Non Operating Income retreated to -$29.0 million in Q2 2026, from $96.0 million in the prior quarter.
- Over five years, Other Non Operating Income peaked at $96.0 million in Q1 2026 and troughed at -$134.0 million in Q4 2022.
- A 5-year average of -$555555.6 and a median of -$6.0 million in 2024 frame the typical range for Other Non Operating Income.
- The widest annual swing landed in 2022, when Other Non Operating Income slumped 13300.0%; it then surged 900.0% in 2026.
- A 5-year view of Other Non Operating Income shows it stood at -$134.0 million in 2022, then jumped by 87.31% to -$17.0 million in 2023, then grew by 11.76% to -$15.0 million in 2024, then soared by 540.0% to $66.0 million in 2025, then tumbled by 143.94% to -$29.0 million in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were -$29.0 million in Q2 2026, $96.0 million in Q1 2026, and $66.0 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.00 Mn |
| Mar 31, 2026 | 96.00 Mn |
| Dec 31, 2025 | -67.00 Mn |
| Sep 30, 2025 | -17.00 Mn |
| Jun 30, 2025 | 35.00 Mn |
| Mar 31, 2025 | 4.00 Mn |
| Dec 31, 2024 | -17.00 Mn |
| Jun 30, 2024 | -6.00 Mn |
| Mar 31, 2024 | -3.00 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Sep 30, 2023 | -14.00 Mn |
| Jun 30, 2023 | -1.00 Mn |
| Mar 31, 2023 | -6.00 Mn |
| Dec 31, 2022 | -32.00 Mn |
| Sep 30, 2022 | -4.00 Mn |
| Jun 30, 2022 | -7.00 Mn |
| Mar 31, 2022 | 4.00 Mn |
| Dec 31, 2021 | -1.00 Mn |
| Sep 30, 2021 | -3.00 Mn |
| Jun 30, 2021 | -20.00 Mn |